Non-Hodgkin's lymphoma

correlation of cell surface marker phenotype with clinical features and prognosis

K. Okabe, H. Toki, Y. Kimura, M. Fujii, Katsuyuki Kiura, S. Moriwaki

Research output: Contribution to journalArticle

Abstract

The correlation of surface marker phenotype with prognosis was analysed in 64 patients with non-Hodgkin's lymphoma who had been treated in Shikoku Cancer Center Hospital. B-cell lymphomas (21 cases) had significantly better prognosis than T-cell lymphomas (21 cases). The complete remission (CR) rate was 52%, and the 50% survival time was 13 months for T-cell lymphomas. All T-cell lymphoma patients died within 31 months. In B-cell lymphomas, on the other hand, the CR rate was 100%, 50% survival time was 30 months, and there were no cases of relapse in patients who had been in continuous CR for more than 2 years. About 40% of B-cell lymphomas appeared to have the potential for cure.

Original languageEnglish
Pages (from-to)2960-2964
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume13
Issue number10
Publication statusPublished - Oct 1986
Externally publishedYes

Fingerprint

T-Cell Lymphoma
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Phenotype
Cancer Care Facilities
Survival
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Non-Hodgkin's lymphoma : correlation of cell surface marker phenotype with clinical features and prognosis. / Okabe, K.; Toki, H.; Kimura, Y.; Fujii, M.; Kiura, Katsuyuki; Moriwaki, S.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 13, No. 10, 10.1986, p. 2960-2964.

Research output: Contribution to journalArticle

@article{50371974fa5146768c709bb6fa39ba4d,
title = "Non-Hodgkin's lymphoma: correlation of cell surface marker phenotype with clinical features and prognosis",
abstract = "The correlation of surface marker phenotype with prognosis was analysed in 64 patients with non-Hodgkin's lymphoma who had been treated in Shikoku Cancer Center Hospital. B-cell lymphomas (21 cases) had significantly better prognosis than T-cell lymphomas (21 cases). The complete remission (CR) rate was 52{\%}, and the 50{\%} survival time was 13 months for T-cell lymphomas. All T-cell lymphoma patients died within 31 months. In B-cell lymphomas, on the other hand, the CR rate was 100{\%}, 50{\%} survival time was 30 months, and there were no cases of relapse in patients who had been in continuous CR for more than 2 years. About 40{\%} of B-cell lymphomas appeared to have the potential for cure.",
author = "K. Okabe and H. Toki and Y. Kimura and M. Fujii and Katsuyuki Kiura and S. Moriwaki",
year = "1986",
month = "10",
language = "English",
volume = "13",
pages = "2960--2964",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "10",

}

TY - JOUR

T1 - Non-Hodgkin's lymphoma

T2 - correlation of cell surface marker phenotype with clinical features and prognosis

AU - Okabe, K.

AU - Toki, H.

AU - Kimura, Y.

AU - Fujii, M.

AU - Kiura, Katsuyuki

AU - Moriwaki, S.

PY - 1986/10

Y1 - 1986/10

N2 - The correlation of surface marker phenotype with prognosis was analysed in 64 patients with non-Hodgkin's lymphoma who had been treated in Shikoku Cancer Center Hospital. B-cell lymphomas (21 cases) had significantly better prognosis than T-cell lymphomas (21 cases). The complete remission (CR) rate was 52%, and the 50% survival time was 13 months for T-cell lymphomas. All T-cell lymphoma patients died within 31 months. In B-cell lymphomas, on the other hand, the CR rate was 100%, 50% survival time was 30 months, and there were no cases of relapse in patients who had been in continuous CR for more than 2 years. About 40% of B-cell lymphomas appeared to have the potential for cure.

AB - The correlation of surface marker phenotype with prognosis was analysed in 64 patients with non-Hodgkin's lymphoma who had been treated in Shikoku Cancer Center Hospital. B-cell lymphomas (21 cases) had significantly better prognosis than T-cell lymphomas (21 cases). The complete remission (CR) rate was 52%, and the 50% survival time was 13 months for T-cell lymphomas. All T-cell lymphoma patients died within 31 months. In B-cell lymphomas, on the other hand, the CR rate was 100%, 50% survival time was 30 months, and there were no cases of relapse in patients who had been in continuous CR for more than 2 years. About 40% of B-cell lymphomas appeared to have the potential for cure.

UR - http://www.scopus.com/inward/record.url?scp=0022792852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022792852&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 2960

EP - 2964

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 10

ER -